Buta Brian, Choudhury Parichoy Pal, Xue Qian-Li, Chaves Paulo, Bandeen-Roche Karen, Shardell Michelle, Semba Richard D, Walston Jeremy, Michos Erin D, Appel Lawrence J, McAdams-DeMarco Mara, Gross Alden, Yasar Sevil, Ferrucci Luigi, Fried Linda P, Kalyani Rita Rastogi
Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Center on Aging and Health, Johns Hopkins University, Baltimore, Maryland.
J Am Geriatr Soc. 2017 Mar;65(3):619-624. doi: 10.1111/jgs.14677. Epub 2016 Dec 23.
Evidence suggests vitamin D deficiency is associated with developing frailty. However, cardiometabolic factors are related to both conditions and may confound and/or mediate the vitamin D-frailty association. We aimed to determine the association of vitamin D concentration with incidence of frailty, and the role of cardiometabolic diseases (cardiovascular disease, diabetes, hyperlipidemia, hypertension) in this relationship.
Prospective longitudinal cohort study (7 visits from 1994-2008).
Baltimore, Maryland.
Three hundred sixty-nine women from the Women's Health and Aging Study II aged 70-79 years, free of frailty at baseline.
Serum circulating 25-hydroxyvitamin D (25[OH]D) concentration was assessed at baseline and categorized as: <10; 10-19.9; 20-29.9; and ≥30 ng/mL. Frailty incidence was determined based on presence of three or more criteria: weight loss, low physical activity, exhaustion, weakness, and slowness. Cardiometabolic diseases were ascertained at baseline. Analyses included Cox regression models adjusted for key covariates.
Incidence rate of frailty was 32.2 per 1,000 person-years in participants with 25(OH)D < 10 ng/mL, compared to 12.9 per 1,000 person-years in those with 25(OH)D ≥ 30 ng/mL (mean follow-up = 8.5 ± 3.7 years). In cumulative incidence analyses, those with lower 25(OH)D exhibited higher frailty incidence, though differences were non-significant (P = .057). In regression models adjusted for demographics, smoking, and season, 25(OH)D < 10 ng/mL (vs ≥30 ng/mL) was associated with nearly three-times greater frailty incidence (hazard ratio (HR) = 2.77, 95% CI = 1.14, 6.71, P = .02). After adjusting for BMI, the relationship of 25(OH)D < 10 ng/mL (vs ≥30 ng/mL) with incident frailty persisted, but was attenuated after further accounting for cardiometabolic diseases (HR = 2.29, 95% CI = 0.92, 5.69, P = .07).
Low serum vitamin D concentration is associated with incident frailty in older women; interestingly, the relationship is no longer significant after accounting for the presence of cardiometabolic diseases. Future studies should explore mechanisms to explain this relationship.
有证据表明维生素D缺乏与衰弱的发生有关。然而,心脏代谢因素与这两种情况都相关,可能会混淆和/或介导维生素D与衰弱之间的关联。我们旨在确定维生素D浓度与衰弱发生率之间的关联,以及心脏代谢疾病(心血管疾病、糖尿病、高脂血症、高血压)在这种关系中的作用。
前瞻性纵向队列研究(1994年至2008年共7次随访)。
马里兰州巴尔的摩。
来自女性健康与衰老研究II的369名70 - 79岁女性,基线时无衰弱。
在基线时评估血清循环25 - 羟基维生素D(25[OH]D)浓度,并分类为:<10;10 - 19.9;20 - 29.9;≥30 ng/mL。根据是否存在三种或更多标准确定衰弱发生率:体重减轻、身体活动量低、疲惫、虚弱和行动迟缓。在基线时确定心脏代谢疾病。分析包括针对关键协变量进行调整的Cox回归模型。
25(OH)D < 10 ng/mL的参与者中,衰弱发生率为每1000人年32.2例,而25(OH)D≥30 ng/mL的参与者中为每1000人年12.9例(平均随访时间 = 8.5±3.7年)。在累积发病率分析中,25(OH)D水平较低者的衰弱发生率较高,尽管差异无统计学意义(P = 0.057)。在针对人口统计学、吸烟和季节进行调整的回归模型中,25(OH)D < 10 ng/mL(与≥30 ng/mL相比)与衰弱发生率高出近三倍相关(风险比(HR) = 2.77,95%置信区间 = 1.14,6.71,P = 0.02)。在调整体重指数后,25(OH)D < 10 ng/mL(与≥30 ng/mL相比)与新发衰弱之间的关系仍然存在,但在进一步考虑心脏代谢疾病后减弱(HR = 2.29,95%置信区间 = 0.92,5.69,P = 0.07)。
血清维生素D浓度低与老年女性新发衰弱有关;有趣的是,在考虑心脏代谢疾病的存在后,这种关系不再显著。未来的研究应探索解释这种关系的机制。